Survival benefit and biomarker of PD‐1 inhibitor combination therapy in first‐line of advanced biliary tract cancer: A retrospective study

Survival benefit and biomarker of PD‐1 inhibitor combination therapy in first‐line of advanced biliary tract cancer: A retrospective study

Abstract Background Immune checkpoint inhibitor (ICI) combination therapies have shown promise in the first‐line treatment of advanced biliary tract cancer (BTC). However, the best partner remains to be validated. Moreover, progress on biomarkers predicting the efficacy of ICI in BTC is slow. This s...

Full description

Bibliographic Details
Main Authors: Jingyi Guo, Qun Zhou, Mingzhen Zhou, Hengheng Dai, Lin Li, Yudong Qiu, Liang Mao, Baorui Liu, Jie Shen
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Cancer Medicine
Subjects:
biliary tract cancer
biomarkers
combination therapy
PD‐1 inhibitors
survival
Online Access:https://doi.org/10.1002/cam4.6628

Internet

https://doi.org/10.1002/cam4.6628

Similar Items